Efficacy of a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel against adult and larval stages of Toxocara cati in cats.
The efficacy of a novel topical combination of fipronil 8.3% (w/v), (S)-methoprene 10% (w/v), eprinomectin 0.4% (w/v), and praziquantel 8.3% (w/v) (BROADLINE(®), Merial) was evaluated against adult and larval Toxocara cati in four controlled studies. All studies included experimentally infected, purpose-bred, short-haired cats. In two studies, 22 or 20 cats harbouring patent infections as confirmed by pre-treatment faecal examination, were included. Within each study, cats were allocated to one of two groups: control or treated. In a further two studies, 30 cats were included in each; cats were allocated to one of three groups: control, treated when T. cati were expected to be either migrating third and/or fourth-stage larvae, or treated when T. cati were expected to be fourth-stage larvae. Cats allocated to the treated groups received a single topical application of the combination product at 0.12 mL/kg bodyweight (10mg fipronil+12 mg (S)-methoprene+0.5mg eprinomectin+10mg praziquantel per kg). For parasite recovery and count, cats were euthanized humanely at different intervals after treatment. In the studies targeting adult T. cati, ascarids were recovered from all controls (range 1-150) while only two worms were isolated from one treated cat. Thus, the efficacy of the novel combination was 99.4% and 100% against adult T. cati. For studies targeting larval T. cati, up to 21 worms were recovered from each of seven or eight of the control cats per study. No T. cati were recovered from the treated cats in two studies, corresponding to 100% efficacy against both, migrating third and/or fourth-stage larvae and luminal fourth-stage larvae. All cats accepted the treatment well and no adverse experiences or other health problems were observed throughout the studies.
Merial GmbH, Kathrinenhof Research Center, 83101 Rohrdorf, Germany. Electronic address: martin.knaus@merial.com.
Martin
M
Knaus
Merial Limited, Duluth, GA 30096, USA.
Christine F
CF
Baker
East Tennessee Clinical Research Inc., Rockwood, TN 37854, USA.
Craig R
CR
Reinemeyer
Merial Limited, Duluth, GA 30096, USA.
S Theodore
ST
Chester
Merial Limited, Duluth, GA 30096, USA.
Joseph
J
Rosentel
Merial GmbH, Kathrinenhof Research Center, 83101 Rohrdorf, Germany.
Steffen
S
Rehbein
D000818:Animals; D000977:Antiparasitic Agents / Q000008:administration & dosage*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004338:Drug Combinations; D005260:Female; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives; D008297:Male; D008726:Methoprene / Q000008:administration & dosage; D059208:Parasite Load; D011223:Praziquantel / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011897:Random Allocation; D014119:Toxocara / Q000502:physiology; D014120:Toxocariasis / Q000188:drug therapy*; D016896:Treatment Outcome
D000977:Antiparasitic Agents; D004338:Drug Combinations; D011720:Pyrazoles; D011223:Praziquantel; D007559:Ivermectin; C101434:eprinomectin; D008726:Methoprene; C082360:fipronil
Cat; Eprinomectin; Larvae; Nematodes; Topical; Toxocara cati